Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 13/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL659349 | 0.87 | ACHE (0.64) | ACHELMNAMKNK1MKNK2ADORA2A | |
| SCHEMBL25819849 | 0.85 | ACHE (0.49) | ACHELMNAMKNK1MKNK2ADORA2A | |
| SCHEMBL12862846 | 0.84 | ACHE (0.47) | ACHELMNAMKNK1MKNK2ADORA2A | |
| SCHEMBL22399206 | 0.81 | ACHE (0.68) | ACHELMNAMKNK1MKNK2 | |
| SCHEMBL30961721 | 0.81 | ACHE (0.51) | ACHELMNAMKNK1MKNK2 | |
| SCHEMBL31612737 | 0.80 | ACHE (0.44) | ACHELMNAMKNK1MKNK2ADORA2A | |
| SCHEMBL29175561 | 0.80 | ACHE (0.54) | ACHELMNAMKNK1MKNK2ADORA2A | |
| SCHEMBL30686643 | 0.80 | ACHE (0.54) | ACHELMNAMKNK1MKNK2ADORA2A | |
| SCHEMBL566139 | 0.79 | ACHE (0.50) | ACHELMNAMKNK1MKNK2MAP4K4 | |
| SCHEMBL6238381 | 0.79 | ACHE (0.67) | ACHELMNAMKNK1MKNK2MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110022875-A | Therapeutic inhibiting compound | 莱福斯希医药公司 | 2019-07-16 | — | — | CN | disclosed |